Journal of thrombosis and haemostasis : JTH · 2026
Rationale for the milvexian dosing in the phase 3 LIBREXIA program.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Weitz Jeffrey I, Harrington Robert A, LIBREXIA Program Executive Council
Аннотация
BACKGROUND: Milvexian is an oral, small-molecule inhibitor of factor (F)XIa undergoing evaluation in phase 3 clinical trials.
OBJECTIVES: This manuscript aimed to explain the rationale underpinning the hypothesis that FXIa may be a safer target for anticoagulants than FXa; describe the pharmacology of milvexian; review the results of the phase 2 trials with milvexian; and detail how the phase 2 program informed the dosing regimens for the phase 3 trials.
METHODS: This narrative review addresses the above objectives with the primary focus on addressing how the milvexian dosing regimens were selected for the phase 3 LIBREXIA program, which compares milvexian with apixaban for atrial fibrillation (AF) in the LIBREXIA AF trial (NCT05757869) and with placebo, in addition to background single or dual antiplatelet therapy, in patients with acute coronary syndrome (ACS) in the LIBREXIA ACS trial (NCT05754957), and for noncardioembolic ischemic stroke and high-risk transient ischemic attack in the LIBREXIA Stroke trial (NCT05702034).
RESULTS: The milvexian dose regimen selected for the LIBREXIA AF trial is 100 mg twice daily, and for the LIBREXIA ACS and Stroke trials, it is 25 mg twice daily.
CONCLUSIONS: The phase 3 LIBREXIA program will determine whether these dose regimens afford safe and effective anticoagulation in approximately 50 000 patients with AF, ACS, or prior stroke.
OBJECTIVES: This manuscript aimed to explain the rationale underpinning the hypothesis that FXIa may be a safer target for anticoagulants than FXa; describe the pharmacology of milvexian; review the results of the phase 2 trials with milvexian; and detail how the phase 2 program informed the dosing regimens for the phase 3 trials.
METHODS: This narrative review addresses the above objectives with the primary focus on addressing how the milvexian dosing regimens were selected for the phase 3 LIBREXIA program, which compares milvexian with apixaban for atrial fibrillation (AF) in the LIBREXIA AF trial (NCT05757869) and with placebo, in addition to background single or dual antiplatelet therapy, in patients with acute coronary syndrome (ACS) in the LIBREXIA ACS trial (NCT05754957), and for noncardioembolic ischemic stroke and high-risk transient ischemic attack in the LIBREXIA Stroke trial (NCT05702034).
RESULTS: The milvexian dose regimen selected for the LIBREXIA AF trial is 100 mg twice daily, and for the LIBREXIA ACS and Stroke trials, it is 25 mg twice daily.
CONCLUSIONS: The phase 3 LIBREXIA program will determine whether these dose regimens afford safe and effective anticoagulation in approximately 50 000 patients with AF, ACS, or prior stroke.